Subcutaneous trastuzumab (Herceptin) . Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab
Prescrire International 24(159): 93
2015
ISSN/ISBN: 1167-7422 PMID: 25941697 Document Number: 679199
Document emailed within 1 workday
Related Documents
2012: Subcutaneous trastuzumab (Herceptin) injection shows promise Oncology 26(9): 873Sliwkowski, M.X.; Lofgren, J.A.; Lewis, G.D.; Hotaling, T.E.; Fendly, B.M.; Fox, J.A. 1999: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Seminars in Oncology 26(4 Suppl. 12): 60-70
Fleming, T.R. 1999: Issues in the design of clinical trials: insights from the trastuzumab (Herceptin) experience Seminars in Oncology 26(4 Suppl. 12): 102-107
Altundag, K. 2017: Predictive markers for trastuzumab-associated cardiac dysfunction in patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab Journal of BUON: Official Journal of the Balkan Union of Oncology 22(3): 801
Sudo, T.; Aruga, A.; Shimizu, K.; Matsushita, N.; Takasaki, K. 2006: OK432-activated natural killer cells enhanced trastuzumab (Herceptin)-mediated antibody-dependent cellular cytotoxicity in patients with advanced cancer Anticancer Research 26(6b): 4327-4333
Rudlowski, C.; Rath, W.; Becker, A.J.; Wiestler, O.D.; Buttner, R. 2001: Trastuzumab and breast cancer New England Journal of Medicine 345(13): 997-998
McArthur, H.L. 2010: Update on administration of adjuvant trastuzumab Clinical Advances in Hematology and Oncology: H&o 8(5): 321
Murphy, C.G.; Fornier, M. 2010: HER2-positive breast cancer: beyond trastuzumab Oncology 24(5): 410-415
Watanabe, T.; Shimizu, C.; Katsumata, N.; Saijo, N. 2000: Trastuzumab for treatment of advanced breast cancers Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 340-344
Okada, Y.; Kaneko, K.; Kanbayashi, C.; Sato, N. 2012: Protocol for administration of trastuzumab based on cardiac function Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(6): 915-919
Heinzl, S. 2000: Trastuzumab. Monoclonal antibody for the treatment of breast cancer Medizinische Monatsschrift für Pharmazeuten 23(11): 350-352
Nicol, M.; Baudet, M.; Cohen Solal, A. 2018: Acute dyspnea after trastuzumab-treated breast cancer La Revue du Praticien 68(3): 303-306
Nohara, T.; Iwamoto, M.; Kobayashi, T.; Lee, S.-W.; Sumiyoshi, K.; Tanigawa, N. 2003: Examination of therapy using trastuzumab in patients with metastatic breast carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(11): 1651-1654
Chien, K.R. 2000: Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity Seminars in Oncology 27(6 Suppl 11: 9
Tahover, E.; Sonnenblick, A.; Peretz, T.; Katz, D. 2012: Update: adjuvant trastuzumab in HER2 positive breast cancer Harefuah 151(1): 37-42 61
Wang, Y.; Li, J-jie.; Di, G-hong.; Lu, J-song.; Wu, J.; Liu, G-yu.; Hu, X-chun.; Wang, Z-hua.; Yang, W-tao.; Shao, Z-min. 2010: Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer Zhonghua Zhong Liu Za Zhi 32(11): 864-867
Słowik, A.; Lelakowska-Pieła, M.; Konduracka, E. 2016: Biochemical predictors of anthracyclin and trastuzumab induced cardiotoxicity in early diagnostics of cardiomyopathy Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 40(235): 40-45
Ates, O.; Sunar, V.; Aslan, A.; Karatas, F.; Sahin, S.; Altundag, K. 2017: The short-term safety of adjuvant paclitaxel plus trastuzumab - a single centre experience Journal of Buon: Official Journal of the Balkan Union of Oncology 22(2): 320-324
Hayashi, M.; Orita, M.; Hironaka, H.; Morita, N. 2014: A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(3): 353-355
Christodoulou, C.; Klouvas, G.; Pateli, A.; Mellou, S.; Sgouros, J.; Skarlos, D.V. 2003: Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer Anticancer Research 23(1b): 737-744